Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report released on Wednesday. The firm issued a hold rating on the stock.

A number of other research analysts have also issued reports on the stock. Lake Street Capital dropped their price objective on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, January 14th.

Ekso Bionics Stock Up 1.6 %

Shares of NASDAQ EKSO opened at $0.64 on Wednesday. The stock has a 50-day moving average price of $0.67 and a two-hundred day moving average price of $0.94. Ekso Bionics has a 12 month low of $0.50 and a 12 month high of $2.50. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The company has a market cap of $14.15 million, a price-to-earnings ratio of -0.99 and a beta of 1.47.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. The company had revenue of $4.13 million during the quarter, compared to analyst estimates of $6.00 million. During the same quarter in the prior year, the business earned ($0.24) EPS. As a group, analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.